376 related articles for article (PubMed ID: 10496984)
1. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN
Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984
[TBL] [Abstract][Full Text] [Related]
2. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor.
Rao CN; Mohanam S; Puppala A; Rao JS
Biochem Biophys Res Commun; 1999 Feb; 255(1):94-8. PubMed ID: 10082661
[TBL] [Abstract][Full Text] [Related]
3. Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2.
Rao CN; Reddy P; Reeder DJ; Liu Y; Stack SM; Kisiel W; Woodley DT
Biochem Biophys Res Commun; 2000 Oct; 276(3):1286-94. PubMed ID: 11027624
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
5. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI.
Rao CN; Cook B; Liu Y; Chilukuri K; Stack MS; Foster DC; Kisiel W; Woodley DT
Int J Cancer; 1998 May; 76(5):749-56. PubMed ID: 9610735
[TBL] [Abstract][Full Text] [Related]
6. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo.
Jin M; Udagawa K; Miyagi E; Nakazawa T; Hirahara F; Yasumitsu H; Miyazaki K; Nagashima Y; Aoki I; Miyagi Y
Gynecol Oncol; 2001 Nov; 83(2):325-33. PubMed ID: 11606093
[TBL] [Abstract][Full Text] [Related]
7. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2.
Rao CN; Reddy P; Liu Y; O'Toole E; Reeder D; Foster DC; Kisiel W; Woodley DT
Arch Biochem Biophys; 1996 Nov; 335(1):82-92. PubMed ID: 8914837
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis.
Mitsudo K; Jayakumar A; Henderson Y; Frederick MJ; Kang Y; Wang M; El-Naggar AK; Clayman GL
Biochemistry; 2003 Apr; 42(13):3874-81. PubMed ID: 12667078
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin.
Boudier C; Cadène M; Bieth JG
Biochemistry; 1999 Jun; 38(26):8451-7. PubMed ID: 10387091
[TBL] [Abstract][Full Text] [Related]
11. Activation of heparin cofactor II by heparin and dermatan sulfate.
Tollefsen DM
Nouv Rev Fr Hematol (1978); 1984; 26(4):233-7. PubMed ID: 6548014
[TBL] [Abstract][Full Text] [Related]
12. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor.
Stalboerger PG; Panetta CJ; Simari RD; Caplice NM
Thromb Haemost; 2001 Sep; 86(3):923-8. PubMed ID: 11583328
[TBL] [Abstract][Full Text] [Related]
13. The role of tissue factor pathway inhibitor-2 in cancer biology.
Sierko E; Wojtukiewicz MZ; Kisiel W
Semin Thromb Hemost; 2007 Oct; 33(7):653-9. PubMed ID: 18000791
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor pathway inhibitor: proposed heparin recognition region.
Harenberg J; Malsch R; Heene DL
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S50-6. PubMed ID: 7647222
[TBL] [Abstract][Full Text] [Related]
15. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2.
Iino M; Foster DC; Kisiel W
Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):40-6. PubMed ID: 9445254
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor pathway inhibitor; its structure, function and clinical significance.
Kato H
Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
[TBL] [Abstract][Full Text] [Related]
17. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
Derechin VM; Blinder MA; Tollefsen DM
J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
[TBL] [Abstract][Full Text] [Related]
18. [Tissue factor pathway inhibitors].
Sierko E; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Jul; 13(73):66-9. PubMed ID: 12362512
[TBL] [Abstract][Full Text] [Related]
19. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
Piro O; Broze GJ
Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
[TBL] [Abstract][Full Text] [Related]
20. Effect of leukocyte proteinases on tissue factor pathway inhibitor.
Petersen LC; Bjørn SE; Nordfang O
Thromb Haemost; 1992 May; 67(5):537-41. PubMed ID: 1519213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
